Oblique Therapeutics today announced that Dr. Jan Lundberg has joined the company as Scientific Advisor

GOTHENBURG, Sweden, May 8, 2026 /PRNewswire/ -- The recruitment represents a significant strategic addition to the company as it continues the development of its innovative drug platform within pain and inflammatory diseases. Dr. Lundberg has had a long and highly successful international...